Literature DB >> 6192235

Pharmacological characterization of substance P-induced nociception in mice: modulation by opioid and noradrenergic agonists at the spinal level.

J L Hylden, G L Wilcox.   

Abstract

Mice were tested for antinociceptive activity after intrathecal injection of opioid or noradrenergic agonists by lumbar puncture. Opioid agonists with mu or delta activity and adrenergic agonists with alpha activity demonstrated dose-related, receptor-mediated analgesia in the tail-flick assay, s.c. hypertonic saline assay and the intrathecal substance P behavioral assay. Inhibition of substance P-induced biting and scratching by intrathecally administered antinociceptive agents is likely mediated by post-synaptic receptors. This action of opioids and norepinephrine was antagonized by their respective pharmacological antagonists. Subanalgesic doses of Leu-enkephalin or norepinephrine potentiated the antinociceptive activity of morphine in the substance P assay. Similarly, opioid agonists potentiated the action of norepinephrine. These results suggest that opioid and alpha adrenergic agonists act on separate receptors to produce a synergistic inhibition of the transmission of nociceptive information at the spinal level.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192235

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception.

Authors:  Arpad Dobolyi; Hiroshi Ueda; Hitoshi Uchida; Miklós Palkovits; Ted B Usdin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

2.  The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy.

Authors:  L S Stone; L B MacMillan; K F Kitto; L E Limbird; G L Wilcox
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

3.  Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level.

Authors:  R M Kream; T Kato; H Shimonaka; J E Marchand; W H Wurm
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

4.  Increased morphine analgesia and reduced side effects in mice lacking the tac1 gene.

Authors:  A Bilkei-Gorzo; J Berner; J Zimmermann; R Wickström; I Racz; A Zimmer
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 5.  Analgesic synergy between opioid and α2 -adrenoceptors.

Authors:  A-J Chabot-Doré; D J Schuster; L S Stone; G L Wilcox
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

6.  CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.

Authors:  Joel E Schlosburg; Scott T O'Neal; Daniel H Conrad; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

7.  Delta-opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones.

Authors:  A F Sullivan; A H Dickenson; B P Roques
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

8.  Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn.

Authors:  Maureen S Riedl; Stephen A Schnell; Aaron C Overland; Anne-Julie Chabot-Doré; Anna M Taylor; Alfredo Ribeiro-da-Silva; Robert P Elde; George L Wilcox; Laura S Stone
Journal:  J Comp Neurol       Date:  2009-04-01       Impact factor: 3.215

9.  An isobolographic analysis of the effects of N-methyl-D-aspartate and NK1 tachykinin receptor antagonists on inflammatory hyperalgesia in the rat.

Authors:  K Ren; M J Iadarola; R Dubner
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

10.  Effects of clonidine and yohimbine on a C-fibre-evoked blood pressure reflex in the rat.

Authors:  J Donnerer; Z Yan; F Lembeck
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.